| ONCE Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the ONCE shares outstanding history going back to 1/30/2015:
Also see: ONCE Market Cap History ONCE YTD Return |
ONCE Shares Outstanding History — Spark Therapeutics Share Count Over Time
As of 11/1/2019 Spark Therapeutics has 38.52 million ONCE shares outstanding. Investors often track the ONCE shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows ONCE share count trends over time, with 23 historical shares outstanding datapoints presented, dating back to 1/30/2015.
| ONCE Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||
ONCE Historical Shares Outstanding: +12.52% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||
| ONCE Stock Price Chart |
| About Spark Therapeutics Inc |
| Spark Therapeutics is engaged in the field of gene therapy. Co. has built a pipeline of gene therapy product candidates that are directed to the retina, the liver and the central nervous system. Co.'s product, LUXTURNA™ (voretigene neparvovec-rzyl), has been approved by the U.S. Food and Drug Administration for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation-associated retinal dystrophy. Co.'s gene therapy product candidates in clinical development include: SPK-8011, Co.'s primary product candidate in the SPK-FVIII program for hemophilia A; SPK-8016, a product candidate for the hemophilia A inhibitor market; and SPK-7001, targeting choroideremia. We show 23 historical shares outstanding datapoints in our coverage of ONCE's shares outstanding history. Understanding the changing numbers of ONCE shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ONCE versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ONCE by allowing them to research ONCE shares outstanding history as well as any other stock in our coverage universe. |
| ONCE Current Stock Quote |
Quotes delayed 20 minutes  Free ONCE Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| ONCE Share Performance |
| Shares Outstanding Peers |
| Spark Therapeutics (ONCE) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
ONCO Shares Outstanding History ONCR Shares Outstanding History ONCS Shares Outstanding History ONCT Shares Outstanding History ONCY Shares Outstanding History ONEM Shares Outstanding History ONS Shares Outstanding History ONTX Shares Outstanding History ONVO Shares Outstanding History OPCH Shares Outstanding History More Healthcare companies » |
ONCE Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
